Planegg/Munich, Germany, December 30, 2019 MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for…Original Article
MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA
